|
gptkbp:instanceOf
|
gptkb:drug
gptkb:ergoline_derivative
|
|
gptkbp:approvalYear
|
1996
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
G02CB03
|
|
gptkbp:brand
|
Cabaser
Dostinex
|
|
gptkbp:CASNumber
|
81409-90-7
|
|
gptkbp:chemicalClass
|
gptkb:alkaloid
|
|
gptkbp:contraindication
|
uncontrolled hypertension
history of cardiac valvulopathy
|
|
gptkbp:developedBy
|
Farmitalia-Carlo Erba
|
|
gptkbp:eliminationHalfLife
|
63-69 hours
|
|
gptkbp:excretion
|
urine
bile
|
|
gptkbp:hasMolecularFormula
|
C26H37N5O2
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
gptkb:dopamine_agonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:proteinBinding
|
41-42%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
constipation
dizziness
fatigue
headache
hypotension
|
|
gptkbp:synonym
|
1-[(6-allylergolin-8β-yl)-carbonyl]-1-(3-dimethylaminopropyl)-3-ethylurea
|
|
gptkbp:usedFor
|
gptkb:hyperprolactinemia
gptkb:Parkinson's_disease
prolactinomas
|
|
gptkbp:bfsParent
|
gptkb:N04BB
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cabergoline
|